Flowtech Fluidpower Posts Widened Loss in 2024 Amid Strategic Restructuring and Acquisitions
Flowtech Fluidpower's 2024 operating loss hits £25.2m amid restructuring & acquisitions, with final dividend axed to preserve cash.
This article covers information on Flowtech Fluidpower PLC.
LON:FLOA Year of Two Halves: Flowtech’s Turbulent 2024 Explained
If ever there was a results announcement that demanded a stiff cup of tea and a forensic eye, Flowtech Fluidpower’s 2024 preliminary results are it. The hydraulic and pneumatic specialist posted a £25.2m operating loss – more than double 2023’s £10.4m deficit – against a backdrop of what Chair Roger McDowell diplomatically calls “persistent market headwinds.” But beneath the red ink lies a fascinating story of strategic gambles, bargain-bin acquisitions, and a business fighting to control the controllables.
The Numbers That Matter
- Revenue: £107.3m (down 4.3% from £112.1m in 2023)
- Gross margin: 38.2% (up 142bps – a rare bright spot)
- Net debt: £15.1m (up £0.4m, but within banking covenants)
- Dividend: Axed (saving £1.4m for restructuring war chest)
The 8.6% like-for-like revenue decline tells its own story. Customers slashed orders, delayed projects, and destocked inventories like Marie Kondo on a bad day. Yet Flowtech still outperformed a hydraulic/pneumatic market that contracted over 10% in 2024. As CEO Mike England puts it: “We’re not relying on a market recovery to drive progress – we’re making our own success.”
The Restructuring Playbook
2024 was all about “heavy lifting” to build what management repeatedly calls a “stable, scalable platform.” Translation? They’ve been busy:
- Cutting £1.5m in annualised costs
- Reducing headcount by 2.2% (on top of prior cuts)
- Slashing inventory by £3m while maintaining 97% service levels
- Rebranding 10 product lines under the unified FT Pro label (now 16% of sales)
The real showstopper? A £25.6m non-cash impairment charge, primarily from writing down goodwill. While eye-watering, this reflects brutal realism about future cash flows rather than immediate operational issues.
Acquisitions: Bargain Hunting or Strategic Masterstroke?
Flowtech’s M&A team earned their spurs in 2024:
1. Thorite (August 2024)
- Paid: £764k for a 174-year-old UK pneumatic specialist
- Assets acquired: £2.7m inventory, 7 branches, 170 years’ expertise
- Result: Turned £1m annual loss into profit within 18 weeks
2. Allswage (March 2025)
- Paid: £50k (yes, fifty thousand) for hydraulic swaging assets
- Assets acquired: £400k book value inventory
- Potential: “Negative goodwill” expected (buying pounds for pennies)
As CFO Russell Cash notes: “When others zig, we zag.” With competitors retrenching, Flowtech’s snapping up distressed assets could prove prescient.
Digital Dawn
While traditional markets floundered, Flowtech’s digital channels quietly gained traction:
- Online orders now 26% of total revenue (up 5%)
- 173,600 web orders processed (2% growth)
- New e-commerce platform launching Q2 2025
The “Amazonification” of industrial distribution is real, and Flowtech’s £1.76m tech investment suggests they’re determined not to be left holding a paper catalogue.
The Road Ahead: Cautious Optimism?
Management’s 2025 playbook focuses on:
- Higher-margin sectors: Defence, data centres, water infrastructure
- Commercial discipline: Targeting £1m+ procurement savings
- Integration: Extracting synergies from Thorite/Allswage
But risks loom large. With 70% UK revenue exposure and “global trade wars” cited as headwinds, Flowtech remains hostage to macroeconomic fortunes. The dividend cut, while prudent, won’t thrill income investors.
The Thompson Take
This is a classic “jam tomorrow” story. The 2024 numbers look grim, but Flowtech’s playing a long game:
- ✅ Margin expansion proves commercial discipline
- ✅ Strategic acquisitions at cycle lows
- ❌ Over-reliance on UK manufacturing recovery
- ❌ Execution risk on digital transformation
As Mike England says: “We’ve built the platform – now we need to perform.” For investors willing to stomach turbulence, Flowtech offers leveraged exposure to industrial automation trends. For the risk-averse? Watch from the sidelines until that £5.9m EBITDA starts climbing.
One to watch – with finger poised over the “buy” button if H1 trading surprises.
Related
Keep reading
Investing
AstraZeneca’s Enhertu delivers Phase III lung cancer PFS win
Enhertu delayed disease progression versus standard care in a Phase III lung cancer trial, supporting its potential move into first-line treatment.
JoshuaAugust 17, 2026
Investing
Optima Health FY26 results: growth beats expectations as PAM integration begins
Optima Health beat adjusted EBITDA expectations in FY26, while the £100 million PAM acquisition reshaped its growth prospects and balance sheet.
JoshuaAugust 17, 2026
Investing
Nostrum Oil & Gas Agrees $304.6 Million Kazakhstan Sale Ahead of Wind-Down
Nostrum plans to sell its Kazakhstan operations, repay secured notes in full and begin an orderly wind-down after completion.
JoshuaAugust 17, 2026
Last updated
Category
InvestingLikes
Star Rating
No ratings yet
Comments
No comments yet - start the conversation.